Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00291525 · ClinicalTrials.gov registry record · NA
Randomized On-X Anticoagulation Trial
A NA study, sponsored by On-X Life Technologies.
- Completed
- Registry status
- NA
- Development phase
- 977
- Enrollment target
NCT00291525 is a NA study that has completed, run by On-X Life Technologies. The registered enrollment target is 977 participants.
The verdict
NCT00291525, a NA study, has completed, sponsored by On-X Life Technologies.
- COMPLETED
- Registry status
- NA
- Development phase
- 977 participants
- Enrollment target
Study Summary
Various patient groups with the On-X Valve can be maintained safely on lower doses of blood thinner(Coumadin®) or on antiplatelet drugs (aspirin/Plavix®) only rather than the standard dose of Coumadin and aspirin presently recommended by ACC/AHA or ACCP professional societies.
Interventions
- DEVICE On-X valve using reduced anticoagulation
- DEVICE On-X Valve with Standard warfarin Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 977 participants |
| Start Date | 2006-06-06 |
| Est. Completion | 2023-12-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00291525
The ClinicalTrials.gov registry entry for NCT00291525 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 977 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is On-X Life Technologies, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which On-X valve using reduced anticoagulation is the first listed.
NCT00291525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00291525 about?
NCT00291525 is a clinical study titled "Randomized On-X Anticoagulation Trial". Various patient groups with the On-X Valve can be maintained safely on lower doses of blood thinner(Coumadin®) or on antiplatelet drugs (aspirin/Plavix®) only rather than the standard dose of Coumadin and aspirin presently recommended by ACC/AHA or ACCP professional societies.
What is the current status of trial NCT00291525?
This trial is currently completed. It is a NA study. The enrollment target is 977 participants. The study started on 2006-06-06. Estimated completion is 2023-12-29.
What interventions are being tested in trial NCT00291525?
The interventions under investigation include: On-X valve using reduced anticoagulation (DEVICE), On-X Valve with Standard warfarin Therapy (DEVICE).
Who is sponsoring clinical trial NCT00291525?
This trial is sponsored by On-X Life Technologies, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.